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Abstract
We have explored morphology of DNA molecules bound with Cu complexes of piroxicam (a non-steroidal anti-inflammatory drug)
molecules under one-dimensional confinement of thin films and have studied the effect of counterions present in a buffer. X-ray
reflectivity at and away from the Cu K absorption edge and atomic force microscopy studies reveal that confinement segregates the
drug molecules preferentially in a top layer of the DNA film, and counterions enhance this segregation.
Introduction
Condensed state behaviour of DNA, the best-known biopoly-
mer, in a confined space is a matter of interest due to its rele-
vance in living systems. Within cells DNA molecules remain in
a confined space crowded by other molecules and ions. Thus,
there are three aspects of the situation, which demand elucida-
tion – the role of the ions, of the molecules (especially macro-
molecules) and of the confinement in the length scales of nano-
meters and micrometers – in maintaining the stability and
homogeneity of the phase of the mixture [1-4] as well as of the
structure of the DNA molecules [5]. Studies on the first aspect
have established that depending on counterion concentrations
and valencies, DNA molecules in bulk solution exhibit isotropic
to liquid crystalline phase transition and under extreme condi-
tions they can form crystalline states [6]. Again, a mixture of
DNA and other macromolecules undergoes spontaneous segre-
gation and organization under micrometre-scale confinement
[7]. Regarding confinement effects at the nanometer scale, we
have observed that in absence of counterions DNA molecules
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form layered structures aligned laterally to the film surface,
whereas in case of films prepared from buffered solution there
is no such layering due to the increased orientational entropy of
entangled shorter DNA molecules [8,9]. This indicates that both
confinement and presence of charged and neutral species in the
environment dictates the structure and dynamics of DNA aggre-
gation and lead us to explore the confinement effect on other bi-
ologically relevant DNA composites.
We have focussed on the effect of one such biologically active
molecule, piroxicam, which is an enolic acid. It is used as a
nonsteroidal anti-inflammatory drug (NSAID) for symptomatic
relief from rheumatoid arthritis, osteoarthritis and spondylitis
[10]. However, the metal-complexes of this molecule form
another group of drugs of even greater interest due to their anti-
cancer activity [11,12]. In this context, the attachment of these
drugs to DNA molecule gains special importance, since this de-
termines their biofunctionality [13,14]. It is already reported
that a Cu(II) complex of piroxicam intercalates within the DNA
backbone [15-17]. Motivated by these observations, we have
studied effect of counterions on the confined state of
metal–drug–DNA complexes, because within living systems
such complexes exist in the presence of various salt ions, in a
highly confined state.
Here we report structural studies of a metal–drug–DNA com-
plex within thin films, i.e., under one-dimensional confinement
and of the influence of counterions on this confined system.
Specifically, we have studied thin films comprising of compos-
ites of DNA and a Cu(II) complex of piroxicam in presence and
absence of buffer molecules. Using anomalous X-ray reflec-
tivity we have probed its out-of-plane structure whereas atomic
force microscopy has provided us its in-plane morphology.
Experimental
Polymerized calf thymus DNA (Sisco Research Laboratory,
India) dissolved in triple-distilled water formed a pristine stock
solution. The absorbance ratio A260/A280 of the solution at 260
and 280 nm being in the range 1.8 < A260/A280 < 1.9, indicat-
ed that no further deproteinization of the solution was neces-
sary. The nucleotide concentration of the stock solution,
assuming ε260 = 6600 M−1cm−1, was found to be 1.8 mM. The
stock solution was diluted to the desired concentration of
800 μM in triple distilled water. 10 mM of sodium cacodylate
(Merck, Germany) solution in triple-distilled water was adjusted
to the desired pH of 6.7 with hydrochloric acid and was used as
stock buffer solution. Each molecule of sodium cacodylate
effectively contributes one Na+ ion.
The Cu–piroxicam complex was synthesized following an
established protocol [18] and was characterized by FTIR, EPR,
and elemental analysis as described in a previous work [19].
Figure 1 shows the structure of the piroxicam molecule along
with its Cu(II) complex. Piroxicam was purchased from Sigma
Chemicals and was used without further purification. A stock
solution of piroxicam of strength 0.5 mM was prepared in spec-
troscopic grade ethanol, because of poor solubility of pirox-
icam in water. CuCl2 was purchased from Sigma Chemicals and
stock solution was prepared by dissolving it in water. Concen-
tration of stock Cu(II)–piroxicam solution was maintained at
37.4 μM. This stock solution was mixed with DNA stock solu-
tion of concentration 800 μM resulting in a fraction of 0.046 of
drug–metal complex in DNA. We have worked with two solu-
tions of drug–metal complexes mixed with DNA, one in pres-
ence and the other in absence of buffer. When mixed with
DNA-buffer solution, the buffer concentration was maintained
at 10 mM.
Figure 1: Structure of (a) piroxicam molecule and (b) Cu(II)–piroxicam
complex.
Films were prepared by spin-coating the solution on amor-
phous fused quartz substrates at ambient condition using a spin-
coater (Headway Research Inc., USA). Before spin-coating the
fused quartz (Alfa Aesar, USA) substrates were cleaned
and hydrophilized by boiling in 5:1:1 H2O/H2O2/NH4OH solu-
tion for 10 min, followed by sonication in acetone and ethanol
respectively, then rinsing by Millipore water (resistivity
≈ 18.2 MΩ·cm) and subsequent removal of water by spinning
the substrate at high speed (4000 rpm).
To extract out-of-plane information specular X-ray reflectivity
profiles of these thin films were recorded with step size 5 mdeg
at the Indian Beamline (BL-18B) at Photon Factory, High
Energy Accelerator Research Organization (KEK), Japan. Both
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Figure 2: AFM height image of (a) Cu(II)-piroxicam-DNA film (scan size 5 μm × 5 μm) and (b) Cu(II)–piroxicam–DNA–buffer film (scan size
5 μm × 5 μm). Insets (a) and (b) show corresponding phase images. Lower panel shows the corresponding line profiles along the blue lines drawn on
respective height images.
anomalous and normal X-ray reflectivity data was collected to
check the spatial distribution of Cu along the film depth. Cu has
two absorption edges in X-ray regime which are at 8.98 keV
(K1 edge) and 1.096 keV (L1 edge). As Indian Beamline oper-
ates within 6–20 keV, anomalous reflectivity data was taken at
K1 absorption edge of Cu (at wavelength 1.38 Å, energy
8.98 keV). For normal X-ray reflectivity we chose a wave-
length which is away from the absorption edge. So we shifted to
energy 11.736 keV which corresponds to wavelength 1.08 Å.
To avoid radiation damage the sample was kept in nitrogen at-
mosphere. To analyse all XRR data we have used Minpack
fitting package [20] based on Levenberg–Marquardt algorithm.
It provides the local minimum of nonlinear least squares func-
tions of several variables. Here an iterative process continues
and termination occurs when the relative error between two
consecutive iterates is below 10−9. Atomic force microscope
(AFM) images recorded in tapping mode using Nanonics Multi-
View1000 with glass tips of about 20 nm diameter, provides
in-plane information. The images were analyzed using WSxM
software [21].
Results and Discussion
Figure 2 shows the topography of the film surfaces as obtained
from AFM. The top surface of the film comprising
drug–metal–DNA complex has a lower height variation (rms
roughness 4.28 Å) whereas the film with added buffer has an
increased roughness (rms roughness 8.97 Å). We took
several images from different regions of the sample. Here we
are reporting the average roughness values from five such dif-
ferent images. For Cu(II)–piroxicam–DNA film rms roughness
is 4.51 Å with a standard deviation of 0.41 Å. For Cu(II)–pirox-
icam–DNA–buffer film rms roughness is 8.35 Å with a relative-
ly high standard deviation of 1.08 Å.
This is also apparent from the typical line profiles shown in
Figure 2. The phase images shown inset indicate the clear pres-
ence of clusters of a material different from the film at the base
of the buffered film, whereas such clustering is not so pro-
nounced in the unbuffered film. We have carried out X-ray
reflectivity (XRR) experiments of the films, which provide us
electron density profiles (EDP) of the film along its depth. To
analyze the anomalous reflectivity profiles we have used the
distorted wave Born approximation (DWBA) method [22,23],
which only requires an ansatz of the average electron density of
the film and provides the electron densities of different “layers”
of the film (of thickness decided by the spatial resolution)
through Fourier transforms [24]. In contrast to the usual anom-
alous scattering analysis formalism [25] here we have not
considered any interfacial width between the “layers”. The
reflectivity profiles of the films and EDPs along the depth of the
film extracted from the fits are shown in Figure 3. It is to be
mentioned that in the DWBA model “layers” do not extend into
the substrate. To plot EDP, as shown in Figure 3b and
Figure 3d, we have further convoluted the DWBA EDP with the
average electron density of the substrate and of air (ρs = 0.68
and ρair = 0) and as well as with the roughnesses of those inter-
faces (σaf ≈ 10 Å and σfs ≈ 7 Å). The values of these parame-
ters were obtained from the DWBA fit and during fit it was
always taken care that the roughness values do not exceed the
“layer” thickness.
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Figure 3: X-ray reflectivity data at and away from Cu absorption edge (up shifted for clarity). Symbols: experimental data points; line: fit with DWBA
formalism. (a) Reflectivity profiles of Cu(II)–piroxicam–DNA film, (b) corresponding EDPs. (c) Reflectivity profiles of Cu(II)–piroxicam–DNA–buffer film,
(d) corresponding EDPs.
We observe that the film prepared from a solution containing no
counterions has a thickness of 42 Å, whereas the film prepared
from solution with added buffer has a lower thickness of 36 Å.
These small thickness values establish that we have succeeded
in creating a confined state of this complex. A reduction of the
film thickness after addition of buffer can be explained through
a better neutralization of DNA molecules by the buffer mole-
cules. This in turn reduces the persistence length of the DNA
molecules, makes them softer and more entangled and hence
more compact [26]. Considering the fact that DNA molecules
have a diameter of 22–26 Å, the magnitude of the film thick-
nesses suggests a lateral alignment of DNA molecules within
the film similar to the case of film formed from “pristine” DNA
molecules [8].
Anomalous X-ray scattering data provides us the distribution of
an effective density of Cu atoms along the film depth. Within
any material X-rays interact with electrons only. Hence, the
presence of a particular element is observed by X-ray, when the
X-ray energy matches with any absorption edge of that element
and the radiation is absorbed. As the beam is no more scattered
by the the electrons of that element, the scattered beam provides
a lower value of electron density. The effective electron densi-
ties for X-ray energies away from edge (ρa(z)) and at the edge




where NCu(z) is the atomic density of the element Cu. It is inde-
pendent of energy and effective atomic number Zeff of the ele-
ment as observed by X-ray. Hence, the difference yields the
effective electron density for the element Cu,
(3)
where . The difference in electron densities,
 represents the abundance of Cu. Figure 4a shows this
variation along the film depth for both films. We observe a rela-
tive abundance of Cu near the air–film interface suggesting a
Cu-rich upper layer for both films. This effect is more en-
hanced in the case of the buffer film, indicating counterions en-
hance the Cu proportion in this layer. This suggests that a
drug–DNA segregation occurs with buffering leaving more
drug–metal composites at the surface increasing its roughness
and clustering as observed from AFM topography (Figure 2). In
Figure 4b we have compared the line profiles drawn over two
images. The horizontal lines denote corresponding average
height of the profiles (6.38 Å and 20.37 Å for without
buffer and with buffer films, respectively). Their difference of
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Figure 4: (a) Variation of ΔρCueff along the film depth for both Cu(II)–piroxicam–DNA and Cu(II)–piroxicam–DNA–buffer films. (b) Comparison of the
line profiles along the blue lines drawn on respective height images of Figure 2. The horizontal lines denote corresponding average heights of the
profiles.
Figure 5: Schematic of (a) metal–drug–DNA film and (b) metal–drug–DNA–buffer film.
approx. 14 Å matches closely with the lateral width of pirox-
icam molecules [28,29].
The structures of piroxicam molecule and Cu(II)–piroxicam
complex as depicted in Figure 1 show a planar structure of the
complex which intercalates in a DNA backbone parallel to the
bases in solution [28]. In our case we observe an asymmetric
distribution of Cu atoms with respect to the DNA molecules
aligned laterally over the hydrophilic substrate leading to a pref-
erential enrichment at the top surface of the films. It was ob-
served earlier [8,19,30] that the negatively charged phosphate
groups of DNA also attach with the hydroxyl-terminated hydro-
philic quartz substrate through short-range interactions such as
hydrogen bonds that dominating over the long-range but weak,
screened Coulomb attraction. Due to this short-range interac-
tion, the hydroxyl-terminated substrate prefers DNA molecules
rather than the neutral metal–drug complex. On the other hand,
at the surface, due to the absence of any such short-range inter-
actions, the intercalation of the Cu(II) complex of piroxicam is
allowed, quite similar to the case of bulk solution. This is
shown in Figure 5a. In presence of counterions, the phosphate
groups of the DNA backbone get neutralized. This causes two
effects, (a) the short-range interactions become even more
dominant causing a stronger adhesion to substrate, (b) the pres-
ence of counterions in buffer solution neutralizes the polyan-
ionic DNA backbone to some extent. Charge neutralization of
the backbone reduces the persistence length of DNA, making it
more floppy. A floppy DNA is better accommodated nearer to
the surface as shown in Figure 5b. Enhanced segmental flexi-
bility of DNA in presence of buffer promotes not only closer
approach to the surface but also helps in orienting the Cu-bear-
ing drug molecule more towards the top. These considerations
qualitatively explain the enrichment of the Cu–drug complex at
the surface and the reduced thickness of the film made from
solution with added buffer. This is shown in Figure 5b.
It is to be noted that we have explored the role of very high salt
concentrations (500 mM) in case of pristine DNA thin films, as
reported in [9]. At such high salt concentrations, we observed
salt crystals over the film. Also at concentrations above
100 mM the persistence length of DNA molecules saturates to
approx. 50 nm due to complete neutralization of DNA back-
bone. At salt concentrations of approx. 10 mM DNA is the
onset of full neutralization. To explore counterion effects we
have restricted ourselves to this onset regime [31].
Conclusion
We have carried out a preliminary exploration of the morpho-
logical effects of counterions on a metal–drug–DNA complex
within a thin film. The metal–drug complex intercalates within
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the DNA backbone and prefers to remain near the top surface of
the film. Addition of buffer molecules results in the presence of
more metal–drug composites at the top surface of the film and a
reduction of the film thickness. We have explained these find-
ings qualitatively, invoking enhanced short-range drug–DNA
and substrate–DNA interactions that are influenced by the
buffer.
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